

DATA SHEET

FITC-Conjugated Anti-Human C4d Antibody (C4dpAb2-FITC)

Cat.no.: BI-RC4D-FITC

Source: rabbit polyclonal

Quantity: 100 µl/vial (125 tests)

Form: Liquid IgG fraction, purified by protein G chromatography. The antibody was conjugated with FITC under optimum conditions. The solution is free of unconjugated FITC.

Immunogen: Synthetic peptide (15-mer peptide corresponding to aa 1242-1256 of C4) specific for human complement split product C4d coupled to KLH (keyhole limpet hemocyanine). The antibody was generated according to a previously published protocol (Ref. 1, Ref. 2).

Specificity: The antibody identifies human complement split product C4d. It specifically reacts with the C4d domain of C4 and therefore also binds to C4 and other C4d-containing split products. A detailed characterization of C4dpAb2 is published in Ref. 3.

Application: The antibody has been tested for the flow cytometric detection of cell- or solidphase-bound C4 and C4d split product of alloantibody-triggered C4d deposition to FlowPRA® Class I and II Screening Test beads (One Lambda, Inc., Canoga Park, CA, USA; Ref. 3). This assay ([C4d]FlowPRA) is applicable for the detection of complement-fixing anti-HLA alloantibodies (Ref. 3, Ref. 4). For [C4d]FlowPRA (see working protocol). A final dilution of 1:50 is recommended.

Stability: One month at +4 °C. For prolonged period of time, aliquot and store at –20 °C to –80 °C. Avoid repeated freeze-thaw cycles. Protect from light.

Shelf life: 2 years from production at –20 °C to –80 °C

Related products: Anti-human C4d Antibody (C4dpAb), Cat.no.: BI-RC4D

Literature

1. Regele H, Exner M, Watschinger B, Wenter C, Wahrmann M, Österreicher C, Säemann MD, Mersich N, Hörl WH, Zlabinger GJ, Böhmig GA. C4d deposition is associated with inferior kidney allograft outcome independ.of cellular rejection. *Nephrol Dial Transplant.* 2001 Oct;16(10):2058-2066.
2. Böhmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J, Säemann MD, Hörl WH, Watschinger B, Regele H. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. *J Am Soc Nephrol.* 2002 Apr;13(4):1091-1099.
3. Wahrmann M, Exner M, Haidbauer B, Schillinger M, Regele H, Körmöczi G, Böhmig GA. [C4d]FlowPRA screening—a specific assay for selective detection of complement-activating anti-HLA alloantibodies. *Hum Immunol.* 2005 May;66(5):526-534
4. Wahrmann M, Exner M, Regele H, Derfler K, Körmöczi GF, Lhotta K, Zlabinger GJ, Böhmig GA. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. *J Immunol Methods.* 2003, 275:149-160.
The antibody is for research only. It is not intended for diagnostic or therapeutic use!

The antibody is for research only. It is not intended for diagnostic or therapeutic use!

rev.no: 190328 (replacing 070723)



Biomedica Medizinprodukte GmbH, A-1210 Wien, Divischgasse 4
Tel. +43/1/291 07 45, Fax +43/1/291 07 6389, E-mail info@bmgrp.com, www.bmgrp.com

BIOMEDICA